Eurofarma constantly invests in research and development (R&D) in order to expand in Brazil and abroad, through the expansion of its portfolio and by offering innovative products. The production of quality medicines makes up one of the company’s mission pillars. With investments above 130 million reais in research and development in 2015, Eurofarma has fulfilled its role among the largest companies in the Brazilian market, with strength in Latin America. By the year 2020, the area of R&D will receive investments of about 20% of the company revenues.
The clinical stage of the products developed by R&D is performed by the Eurofarma Clinical Research Area, which works together with renowned physicians in their specialties, and a multidisciplinary team in the design of their clinical protocols, with studies in the therapeutic areas of: rheumatology, endocrinology, infectious diseases, oncology, neurology, pulmonology and cardiology. The research of biotechnological products such as biosimilars, is also part of the scope of the Company’s Research and Development. Over the past 10 years, this sector conducted more than 40 clinical studies in phases I, II and III, generating 13 products, 8 of them already registered in Brazil. Among the most recent records obtained are: FIPRIMA® (filgrastim), LUGANO® (Formoterol + Fluticasone) and PERLATTE® (Lactase).
Radical products are in the Company’s crosshairs, with investment from the earliest stages of discovery of a new compound, so that after all the pre-clinical _ (in vitro and in vivo) and clinical (human beings) tests are performed, new medications can reach the population.
The Clinical Research area also includes the development of generic and similar medications (brand) which hold much of the product portfolio. For the registration of generic similar drugs, studies of Relative Bioequivalence / Bioavailability in healthy volunteers are conducted. This type of study comprises the checking of the absence of a significant difference between the bioavailability of the same active principle of two pharmaceutical equivalent products (or pharmaceutical alternatives) when both are administered at the same dosage and under similar conditions in an appropriate design study. In addition to the human health, the large-size animal segment _ products (mainly cattle) and swine are also the responsibility of the Clinical Research area. _ For proof of effectiveness and safety of these medications, several studies are conducted in target species, and only after approval by the Ministry of Agriculture and Livestock, products are marketed.
Health professionals and research centers that are interested in participating or learning more about the work of Eurofarma in this area can send an e-mail to firstname.lastname@example.org